| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
CELU Stock Overview
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases.
Celularity Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.69 |
| 52 Week High | US$13.19 |
| 52 Week Low | US$1.35 |
| Beta | 0.21 |
| 1 Month Change | -24.22% |
| 3 Month Change | -41.52% |
| 1 Year Change | -68.82% |
| 3 Year Change | -83.00% |
| 5 Year Change | n/a |
| Change since IPO | -82.76% |
Recent News & Updates
Shareholder Returns
| CELU | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.7% | 4.2% | 1.5% |
| 1Y | -68.8% | -7.4% | -14.9% |
Return vs Industry: CELU underperformed the US Biotechs industry which returned -7.4% over the past year.
Return vs Market: CELU underperformed the US Market which returned -14.9% over the past year.
Price Volatility
| CELU volatility | |
|---|---|
| CELU Average Weekly Movement | 14.8% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: CELU is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: CELU's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 225 | Bob Hariri | https://www.celularity.com |
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company’s lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn’s disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy.
Celularity Inc. Fundamentals Summary
| CELU fundamental statistics | |
|---|---|
| Market Cap | US$245.07m |
| Earnings (TTM) | -US$14.28m |
| Revenue (TTM) | US$18.70m |
13.1x
P/S Ratio-17.2x
P/E RatioIs CELU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CELU income statement (TTM) | |
|---|---|
| Revenue | US$18.70m |
| Cost of Revenue | US$19.08m |
| Gross Profit | -US$376.00k |
| Other Expenses | US$13.91m |
| Earnings | -US$14.28m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.098 |
| Gross Margin | -2.01% |
| Net Profit Margin | -76.37% |
| Debt/Equity Ratio | 23.9% |
How did CELU perform over the long term?
See historical performance and comparison